Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (8)

1

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

enthalten in: Cancer discovery | 2017

von de Bono, J. | Ramanathan, R. | Mina, L. | +13

2

Strategies Employed for the Development of PARP Inhibitors

enthalten in: Methods in molecular biology (Clifton, N.J.) | 2017

von Canan, S. | Maegley, K. | Curtin, N.

3

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia

enthalten in: Oncotarget | 2015

von Herriott, A. | Tudhope, S. | Junge, G. | +13

4

PARP inhibitors for anticancer therapy

enthalten in: Biochemical Society transactions | 2014

von Curtin, N.

5

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

enthalten in: Cancer chemotherapy and pharmacology | 2010

von Zaremba, T. | Thomas, H. | Cole, M. | +2

6

Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation

enthalten in: International journal of radiation oncology, biology, physics | 2009

von Mitchell, J. | Smith, G. | Curtin, N.

7

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2009

von Daniel, R. | Rozanska, A. | Thomas, H. | +9

8

PARP inhibitors for cancer therapy

enthalten in: Expert reviews in molecular medicine | 2005

von Curtin, N.

1
[1]